Literature DB >> 24786790

Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Man-Li Luo1, Chang Gong2, Chun-Hau Chen1, Daniel Y Lee1, Hai Hu1, Pengyu Huang1, Yandan Yao1, Wenjun Guo3, Ferenc Reinhardt3, Gerburg Wulf1, Judy Lieberman4, Xiao Zhen Zhou1, Erwei Song2, Kun Ping Lu5.   

Abstract

Breast cancer stem-like cells (BCSC) have been implicated in tumor growth, metastasis, drug resistance, and relapse but druggable targets in appropriate subsets of this cell population have yet to be identified. Here we identify a fundamental role for the prolyl isomerase Pin1 in driving BCSC expansion, invasiveness, and tumorigenicity, defining it as a key target of miR200c, which is known to be a critical regulator in BCSC. Pin1 overexpression expanded the growth and tumorigenicity of BCSC and triggered epithelial-mesenchymal transition. Conversely, genetic or pharmacological inhibition of Pin1 reduced the abundance and self-renewal activity of BCSC. Moreover, moderate overexpression of miR200c-resistant Pin1 rescued the BCSC defect in miR200c-expressing cells. Genetic deletion of Pin1 also decreased the abundance and repopulating capability of normal mouse mammary stem cells. In human cells, freshly isolated from reduction mammoplasty tissues, Pin1 overexpression endowed BCSC traits to normal breast epithelial cells, expanding both luminal and basal/myoepithelial lineages in these cells. In contrast, Pin1 silencing in primary breast cancer cells freshly isolated from clinical samples inhibited the expansion, self-renewal activity, and tumorigenesis of BCSC in vitro and in vivo. Overall, our work demonstrated that Pin1 is a pivotal regulator acting downstream of miR200c to drive BCSC and breast tumorigenicity, highlighting a new therapeutic target to eradicate BCSC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24786790      PMCID: PMC4079726          DOI: 10.1158/0008-5472.CAN-13-2785

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Graphical representation of a generalized linear model-based statistical test estimating the fit of the single-hit Poisson model to limiting dilution assays.

Authors:  T Bonnefoix; P Bonnefoix; M Callanan; P Verdiel; J J Sotto
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

2.  Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation.

Authors:  Takafumi Uchida; Mari Takamiya; Morito Takahashi; Hitoshi Miyashita; Hisafumi Ikeda; Toru Terada; Yo Matsuo; Mikako Shirouzu; Shigeyuki Yokoyama; Fumihiro Fujimori; Tony Hunter
Journal:  Chem Biol       Date:  2003-01

3.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

4.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis.

Authors:  Gerburg Wulf; Priti Garg; Yih-Cherng Liou; Dirk Iglehart; Kun Ping Lu
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

6.  The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer.

Authors:  Gustavo Ayala; Dagong Wang; Gerburg Wulf; Anna Frolov; Rile Li; Janusz Sowadski; Thomas M Wheeler; Kun Ping Lu; Lere Bao
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells.

Authors:  Akihide Ryo; Yih-Cherng Liou; Gerburg Wulf; Masafumi Nakamura; Sam W Lee; Kun Ping Lu
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers.

Authors:  Lere Bao; Amy Kimzey; Guido Sauter; Janusz M Sowadski; Kun Ping Lu; Da-Gong Wang
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Substrate-based design of reversible Pin1 inhibitors.

Authors:  Yixin Zhang; Susanne Füssel; Ulf Reimer; Mike Schutkowski; Gunter Fischer
Journal:  Biochemistry       Date:  2002-10-01       Impact factor: 3.162

10.  The -842G/C polymorphisms of PIN1 contributes to cancer risk: a meta-analysis of 10 case-control studies.

Authors:  Hui-Rong Xu; Zhong-Fa Xu; Yan-Lai Sun; Jian-Jun Han; Zeng-Jun Li
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

View more
  40 in total

Review 1.  Landscape of Pin1 in the cell cycle.

Authors:  Cheng-Han Lin; Hao-Yi Li; Yu-Cheng Lee; Marcus J Calkins; Kuen-Haur Lee; Chia-Ning Yang; Pei-Jung Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

2.  Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.

Authors:  Yuji Sakuma; Hirotaka Nishikiori; Sachie Hirai; Miki Yamaguchi; Gen Yamada; Atsushi Watanabe; Tadashi Hasegawa; Takashi Kojima; Toshiro Niki; Hiroki Takahashi
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

3.  Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways.

Authors:  Zhenzhen Zhang; Weixing Yu; Min Zheng; Xinhua Liao; Jichuang Wang; Dayun Yang; Wenxian Lu; Long Wang; Sheng Zhang; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Mol Carcinog       Date:  2019-04-26       Impact factor: 4.784

4.  A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.

Authors:  Dayun Yang; Wensong Luo; Jichuang Wang; Min Zheng; Xin-Hua Liao; Nan Zhang; Wenxian Lu; Long Wang; Ai-Zheng Chen; Wen-Guo Wu; Hekun Liu; Shi-Bin Wang; Xiao Zhen Zhou; Kun Ping Lu
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

Review 5.  PIN1 in breast development and cancer: a clinical perspective.

Authors:  Alessandra Rustighi; Alessandro Zannini; Elena Campaner; Yari Ciani; Silvano Piazza; Giannino Del Sal
Journal:  Cell Death Differ       Date:  2016-11-11       Impact factor: 15.828

6.  Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.

Authors:  Man-Li Luo; Fang Zheng; Wenying Chen; Zhi-Mei Liang; Gurushankar Chandramouly; Jianan Tan; Nicholas A Willis; Chun-Hau Chen; Mateus de Oliveira Taveira; Xiao Zhen Zhou; Kun Ping Lu; Ralph Scully; Gerburg M Wulf; Hai Hu
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

Review 7.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

Review 8.  The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Authors:  Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Rev Cancer       Date:  2016-06-03       Impact factor: 60.716

9.  Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.

Authors:  Alexandra L Thomas; Hanne Lind; Angela Hong; Danijela Dokic; Kailey Oppat; Elana Rosenthal; Amina Guo; Aaron Thomas; Randala Hamden; Jacqueline S Jeruss
Journal:  Cell Cycle       Date:  2017-07-05       Impact factor: 4.534

10.  Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy.

Authors:  Aili Zhang; Weiwei Tao; Kui Zhai; Xiaoguang Fang; Zhi Huang; Jennifer S Yu; Andrew E Sloan; Jeremy N Rich; Wenchao Zhou; Shideng Bao
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.